Memantine

Generic Name: Memantine

Brand Names: Axura, Ebixa, Marixino, Namenda, Namenda 49 Titration Pack, Namzaric, Nemdatine, Memantine Mylan, Memantine ratiopharm, Memantine Merz, Marixino (previously Maruxa), Memantine Accord, Memantine LEK

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₂₁N

CAS Number: 19982-08-2

Unique Ingredient Identifier: W8O17SJF3T

Background: Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease . ...

Indication: Memantine is used to manage moderate to severe Alzheimer's dementia .
...

Associated Conditions: Alzheimer's Disease (AD), Moderate to Severe Alzheimer's Disease, Mild Vascular dementia, Moderate Alzheimer's Type Dementia, Moderate Vascular dementia, Severe Alzheimer's Type Dementia

Associated Therapies: -

Clinical Trials

Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease

Phase 4

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: placebo
Drug: Memantine

First Posted Date: 2007-05-04

Last Posted Date: 2009-12-24

Lead Sponsor: Forest Laboratories

Target Recruit Count: 265

Registration Number: NCT00469456

Locations: 🇿🇦
Forest Investigative Site, Cape Town, W. Cape, South Africa

Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury

Phase 4

Terminated

Conditions: Traumatic Brain Injury

Interventions: Drug: Placebo
Drug: Memantine

First Posted Date: 2007-04-18

Last Posted Date: 2017-01-23

Lead Sponsor: University of Missouri-Columbia

Target Recruit Count: 11

Registration Number: NCT00462228

Locations: 🇺🇸
University of Missouri-Columbia, Columbia,, Missouri, United States

A Pilot Clinical Trial Of Memantine for Essential Tremor

Phase 4

Completed

Conditions: Essential Tremor

Interventions: Drug: Memantine

First Posted Date: 2007-02-26

Last Posted Date: 2012-06-22

Lead Sponsor: VA Greater Los Angeles Healthcare System

Target Recruit Count: 16

Registration Number: NCT00439699

Locations: 🇺🇸
VA Greater Los Angeles, Los Angeles, California, United States

The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Memantine

First Posted Date: 2006-12-11

Last Posted Date: 2011-03-02

Lead Sponsor: University of Alberta

Target Recruit Count: 42

Registration Number: NCT00409721

Locations: 🇨🇦
Calgary ALS Neuromuscular Clinic, Calgary, Alberta, Canada
🇨🇦
University of Alberta ALS Clinic, Edmonton, Alberta, Canada

Memantine for Agitation and Aggression in Severe Alzheimer's Disease

Phase 4

Completed

Conditions: Alzheimer's Disease

First Posted Date: 2006-11-17

Last Posted Date: 2024-01-31

Lead Sponsor: Sunnybrook Health Sciences Centre

Target Recruit Count: 31

Registration Number: NCT00401167

Locations: 🇨🇦
North York General Hospital, Toronto, Ontario, Canada
🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Memantine for Agitation in Dementia

Phase 4

Completed

Conditions: DEMENTIA

First Posted Date: 2006-09-01

Last Posted Date: 2022-04-06

Lead Sponsor: East Kent Hospitals University NHS Foundation Trust

Target Recruit Count: 153

Registration Number: NCT00371059

Locations: 🇬🇧
Oxleas Nhs Foundation Trust, Dartford, Kent, United Kingdom
🇬🇧
Kent and Medway NHS and Social Care Partnership Trust, Folkestone, Kent, United Kingdom

Memantine Augmentation of Antidepressants

Phase 4

Completed

Conditions: Depressive Disorder

Interventions: Drug: Placebo
Drug: memantine

First Posted Date: 2006-06-27

Last Posted Date: 2018-07-11

Lead Sponsor: University of Massachusetts, Worcester

Target Recruit Count: 31

Registration Number: NCT00344682

Locations: 🇺🇸
Center for Psychopharmacologic Research and Treatment (University of Massachusetts Medical School), Worcester, Massachusetts, United States

Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)

Phase 4

Completed

Conditions: Alzheimer's Disease

First Posted Date: 2006-06-08

Last Posted Date: 2008-01-07

Lead Sponsor: Forest Laboratories

Target Recruit Count: 75

Registration Number: NCT00334906

Locations: 🇺🇸
Forest Laboratories, Jersey City, New Jersey, United States

An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder

Phase 4

Completed

Conditions: Binge Eating Disorder

First Posted Date: 2006-05-29

Last Posted Date: 2007-08-14

Lead Sponsor: Mclean Hospital

Target Recruit Count: 15

Registration Number: NCT00330655

Locations: 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States

Prophylactic Effect of Memantine in Chronic Tension-Type Headache

Phase 3

Completed

Conditions: Tension-Type Headache

First Posted Date: 2006-04-19

Last Posted Date: 2009-02-20

Lead Sponsor: Danish Headache Center

Target Recruit Count: 40

Registration Number: NCT00315666

Locations: 🇩🇰
Danish Headaches Center, Glostrup, Denmark

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy